Pro Dex (PDEX) Stock Price, Financials & Analysis

Key Stats

Market Cap200.62 Mn

P/E14.68

P/S2.59

Div. Yield0.00

Total Debt (Qtr)34.98 Mn

Revenue Growth (1y) (Qtr)16.64

Add ratio to table…

About

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery powered, and electric multifunction surgical drivers and shavers used primarily in the orthopedic, thoracic, and craniomaxillofacial markets. The company also manufactures rotary air motors for various industries, though this activity represents a de minimis portion of its business. The company generates revenue primarily from the sale of medical devices, which accounted for 72%…

The company generates revenue primarily from the sale of medical devices, which accounted for 72% of total sales in fiscal 2025, and from repair services, which contributed 28% of sales in the same period. Additional revenue streams include nonrecurring engineering services, dental components, and industrial and scientific products, each representing about 1% of sales. Medical device products are sold to original equipment manufacturers, while repair services are provided to the same customers, and rotary air motors are sold to a broad range of distributors and end users.

The company operates through the following segments.

Medical Devices: This segment focuses on the design, development, and manufacture of autoclavable, battery powered, and electric multifunction surgical drivers and shavers for orthopedic, thoracic, and craniomaxillofacial markets, and provides repair services for medical devices.

Pro-Dex operates in intensely competitive markets for medical devices, where it faces competition from larger companies with greater name recognition and more substantial financial, technical, and marketing resources. The company’s competitive advantages include its patented adaptive torque limiting technology, proprietary sealing solutions, and compliance with FDA and ISO standards, which help differentiate its products. Despite these strengths, the company must contend with competitive pressures that could affect pricing and market share.

The company’s customers consist primarily of original equipment manufacturers in the medical device industry that purchase its surgical devices and repair services, as well as distributors and end users for its rotary air motors. In fiscal 2025, the top three customers accounted for approximately 94% of sales, with the largest customer representing about 75% of total revenue.

How Pro Dex ranks

Ranked against the 247 companies in Medical Devices and Diagnostics58 metrics · as of Oct 23, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/E 14.7xMedian 29.7x 96^th
P/FCF 29.4xMedian 24.8x 76^th
P/Operating cash flow 27.4xMedian 20.2x 72^nd
P/S 2.56xMedian 3.03x 55^th
P/B 4.17xMedian 2.42x 33^rd
P/Tangible book 4.23xMedian 3.04x 38^th
EV/EBITDA 15.6xMedian 18.0x 83^rd
EV/EBIT 17.3xMedian 27.0x 94^th
EV/Revenue 2.89xMedian 3.09x 54^th
EV/FCF 33.2xMedian 26.4x 75^th
EV/Operating cash flow 31.0xMedian 21.5x 69^th
PEG (3Y EPS CAGR) 0.52Median 0.97 69^th

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 16.4%Median 9.0% 65^th
Revenue CAGR (3Y) 18.9%Median 8.4% 72^nd
Gross profit growth (1Y) 24.7%Median 12.5% 72^nd
Gross profit CAGR (3Y) 24.0%Median 8.7% 77^th
Operating income growth (1Y) 21.5%Median 9.1% 67^th
Operating income CAGR (3Y) 31.1%Median 8.1% 78^th
Net income growth (1Y) 52.2%Median 8.7% 77^th
Net income CAGR (3Y) 24.5%Median 9.3% 73^rd
EPS growth (1Y) 54.2%Median 27.7% 69^th
EPS CAGR (3Y) 28.4%Median 21.0% 60^th
Operating cash flow growth (1Y) 531%Median 5.7% 99^th
Operating cash flow CAGR (3Y) 9.9%Median 11.3% 46^th
Free cash flow growth (1Y) 331%Median 4.5% 96^th
Free cash flow CAGR (3Y) 14.6%Median 14.4% 51^st

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 31.4%Median 58.4% 12^th
EBITDA margin 18.6%Median −4.3% 80^th
Operating margin 16.8%Median −11.1% 87^th
Pretax margin 23.2%Median −13.5% 96^th
Net margin 17.6%Median −15.0% 91^st
FCF margin 8.7%Median −2.7% 71^st
Operating cash flow margin 9.3%Median −0.5% 66^th
Return on equity 29.4%Median −23.9% 97^th
Return on assets 18.3%Median −17.6% 99^th
Return on invested capital 12.0%Median 0.9% 89^th
Return on capital employed 21.0%Median −16.8% 97^th
Asset turnover 1.04xMedian 0.57x 85^th
Cash conversion (OCF / net income) 0.53xMedian 1.51x 17^th
Stock comp / revenue 0.9%Median 5.9% 95^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 47.0%Median 29.9% 25^th
Debt / equity 0.73xMedian 0.47x 31^st
Net debt / EBITDA 1.78xMedian 2.12x 56^th
Debt / FCF 5.18xMedian 4.03x 37^th
Liabilities / assets 36.1%Median 45.5% 59^th
Equity / assets 63.9%Median 54.5% 59^th
Interest coverage 16.0xMedian −2.13x 94^th
Current ratio 4.10xMedian 2.99x 64^th
Quick ratio 2.36xMedian 1.83x 61^st
Cash ratio 0.72xMedian 1.15x 36^th
Altman Z-score 7.60Median 1.47 82^nd

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	250.13 Bn	35.90	5.40	42.55 Bn
2	ABT	Abbott Laboratories	180.31 Bn	33.24	3.87	32.61 Bn
3	DHR	Danaher Corp /De/	162.34 Bn	40.54	6.47	26.56 Bn
4	ISRG	Intuitive Surgical Inc	158.13 Bn	53.47	13.66	-
5	MDT	Medtronic plc	122.37 Bn	23.39	3.26	28.15 Bn
6	SYK	Stryker Corp	117.89 Bn	31.61	4.56	14.94 Bn
7	BSX	Boston Scientific Corp	67.15 Bn	18.27	3.20	12.62 Bn
8	PDEX	Pro Dex Inc	0.20 Bn	14.68	2.59	0.03 Bn

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

TMO

Thermo Fisher Scientific Inc.

250.13 Bn

35.90

5.40

42.55 Bn

ABT

Abbott Laboratories

180.31 Bn

33.24

3.87

32.61 Bn

DHR

Danaher Corp /De/

162.34 Bn

40.54

6.47

26.56 Bn

ISRG

Intuitive Surgical Inc

158.13 Bn

53.47

13.66

MDT

Medtronic plc

122.37 Bn

23.39

3.26

28.15 Bn

SYK

Stryker Corp

117.89 Bn

31.61

4.56

14.94 Bn

BSX

Boston Scientific Corp

67.15 Bn

18.27

3.20

12.62 Bn

PDEX

Pro Dex Inc

0.20 Bn

14.68

2.59

0.03 Bn

Pro Dex PDEX

About

Timing of Transfer of Good or Service Breakdown of Revenue (2026)

Concentration Risk By Type Breakdown of Revenue (2026)

How Pro Dex ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Pro Dex PDEX

About

Timing of Transfer of Good or Service Breakdown of Revenue (2026)

Concentration Risk By Type Breakdown of Revenue (2026)

How Pro Dex ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password